We are pleased to announce that Mr. Daisuke Tanida, former President and CEO of TANITA Corporation, has joined our company as Chief Strategy Officer (CSO).
MediScan Inc. Welcomes Former TANITA President Daisuke Tanida as Chief Strategy Officer (CSO)
— A New Step Toward Global Expansion of Innovative Early Breast Cancer Detection Technology —
MediScan Inc. (Headquarters: Ginza, Chuo-ku, Tokyo; CEO: Koichiro Yoshino; hereinafter “MediScan”) is a medical venture company engaged in the research and development of breath analysis devices for the non-invasive detection of breast cancer. We are pleased to announce that Mr. Daisuke Tanida, former President and CEO of TANITA Corporation, has joined MediScan as Chief Strategy Officer (CSO).
Profile of Daisuke Tanida
Daisuke Tanida is one of Japan’s most distinguished business leaders, known for developing and commercializing the world’s first home body fat monitor and transforming TANITA Corporation — then facing a management crisis — into the world’s No. 1 company in health monitor sales. During his tenure at TANITA, he spearheaded numerous innovations that fused health and business management, including global business expansion into major overseas markets and the success of the “TANITA Employee Cafeteria” initiative. Even after stepping down, he has continued to be involved in corporate turnarounds and new business development, bringing extensive knowledge and experience in the healthcare sector.
About Our Innovative Breast Cancer Screening Technology
In Japan, where breast cancer screening rates remain low compared to other developed countries, MediScan is working to promote an early detection system using breath analysis technology that involves no pain or radiation exposure. Our breath-based breast cancer screening device is an innovative technology that detects breast cancer with high accuracy by analyzing volatile organic compounds (VOCs) in exhaled breath.
Key Features of Our Breath-Based Breast Cancer Screening Device
- Non-invasive: A screening method free from pain and radiation exposure
- High accuracy: Highly precise detection of breast cancer
- Simplicity: Testing completed in just a few minutes
- Scalability: Ongoing research into applications for other types of cancer and chronic diseases beyond breast cancer
Having undergone numerous clinical trials, the technology is now in its final stages toward practical implementation. With Mr. Tanida’s participation, we will further strengthen our business strategy and accelerate expansion into global markets.
Comment from Daisuke Tanida
“MediScan’s innovative technology has the potential to bring transformative change to medical settings not only in Japan but around the world. Improving breast cancer screening rates is a global challenge, and a painless, simple screening method like the breath-based breast cancer detection device has the potential to save the lives of many women. I hope to leverage my experience to contribute, together with MediScan, to realizing next-generation healthcare.”
Future Outlook
Leveraging Mr. Tanida’s outstanding leadership and extensive business development experience, MediScan Inc. will pursue the following initiatives under the mission of “transforming healthcare through cutting-edge technology”:
- Completion of domestic clinical trials and obtaining regulatory approval
- Promoting the adoption of breath-based breast cancer screening devices at domestic medical institutions
- Expansion into global markets, starting with the United States
- Advancing research into applications for other types of cancer and chronic diseases beyond breast cancer
- Developing commercial utilization strategies for big data based on breath analysis data
We will continue to dedicate ourselves to the development and dissemination of innovative medical technologies that contribute to improving the quality of life (QOL) of patients and the medical community.
Related Links:
Click here for the full press release on PR TIMES
Contact Information
MediScan Inc.
TEL: 03-6280-6895
E-mail: info@mediscan.co.jp